Real-World Case Studies Showing the Effective Use of Azelaic Acid in the Treatment, and During the Maintenance Phase, of Adult Female Acne Patients

Figures & data

Table 1 Characteristics of Adolescent and Adult Female Acne^16,18,19,26

Characteristic	Adolescent Acne	Adult Female Acne
Typical location	Forehead, nose, upper chin (T-zone)^Citation18	Cheeks, around the mouth, lower chin (U-zone)^Citation18
Morphological characteristics	All type of acne lesions^Citation18	Two clinical profiles:^Citation18 Hyperseborrhea, non-inflammatory lesions Superficial inflammatory lesions, deep seated nodules and cysts
Severity	Mild-to-severe, often severe^Citation19	Mild-to-moderate^Citation18
Duration	Months to years, during adolescence^Citation26	Can last a lifetime after it starts^Citation26
Skin sensitivity	Normal^Citation26	Affected by skin aging process^Citation26
Impact on quality of life	Major impact on self-esteem^Citation16	Greater impact than on younger people; affects self-esteem and body satisfaction^Citation16

Figure 1 Case study 1 improvement on left-hand side of face, baseline to 6 months (a) Baseline (b) 3 months with AZA 15% gel twice daily (c) 6 months with AZA 15% gel twice daily.

Figure 2 Case study 1 improvement on right-hand side of face, baseline to 6 months (a) Baseline (b) 3 months with AZA 15% gel twice daily (c) 6 months with AZA 15% gel twice daily.

Figure 3 Case study 2 improvement on right-hand side of face, baseline to 6 months (a) Baseline (b) 3 months with AZA 15% gel twice daily (c) 6 months with AZA 15% gel twice daily.

Figure 4 Case study 2 improvement on left-hand side of face, baseline to 6 months (a) Baseline (b) 3 months with AZA 15% gel twice daily (c) 6 months with AZA 15% gel twice daily.

Figure 5 Case study 3 improvement on both sides of face, baseline to 9 months. (a) Baseline (b) 9 months with spironolactone 50mg twice a day plus AZA 15% gel twice a day.

Figure 6 Case study 3 improvement on both sides of face, baseline to 9 months (a) Baseline (b) 9 months with spironolactone 50mg twice a day plus AZA 15% gel twice a day.

Figure 7 Case study 3 improvement right side, baseline to 18 months (a) Baseline following 9 months with spironolactone 50mg twice a day plus AZA 15% gel twice a day (b) 9 months with spironolactone 25mg twice a day plus AZA 15% gel twice a day.

Figure 8 Case study 3 improvement left side, baseline to 18 months (a) Baseline following 9 months with spironolactone 50mg twice a day plus AZA 15% gel twice a day (b) 9 months with spironolactone 25mg twice a day plus AZA 15% gel twice a day.

Figure 9 Case study 4 improvement on right-hand side of face, baseline to 9 months (a) Baseline (b) 9 months with COC (ethinylestradiol 0.02mg plus drospirenone 3mg) plus spironolactone 25mg twice a day, plus AZA gel 15% twice daily.

Figure 10 Case study 4 improvement on left-hand side of face, baseline to 9 months (a) Baseline (b) 9 months with COC (ethinylestradiol 0.02mg plus drospirenone 3mg) plus spironolactone 25mg twice a day, plus AZA gel 15% twice daily.

Figure 11 Case study 5 improvement on left-hand side of face, baseline to 4 months (a) Baseline (b) 4 months with oral contraceptive (ethinylestradiol plus chlormadinone) plus AZA 15% gel twice a day.

Figure 12 Case study 5 improvement on right-hand side of face, baseline to 4 months (a) Baseline (b) 4 months with oral contraceptive (ethinylestradiol plus chlormadinone) plus AZA 15% gel twice a day.

Figure 13 Case study 6 improvement on left-hand side of face, baseline to 6 months. (a) No response after 6 months with spiro 100 mg / day + tretinoin 0.05% gel at night. (b) 3 months with bicalutamide 50 mg / 3 times per week + AZA 15% gel twice daily. (c) 3 months with bicalutamide 50 mg two times per week + AZA 15% gel twice daily.

Dréno B, Layton A, Zouboulis C, et al. Adult female acne: a new paradigm. J Eur Acad Dermatol Venereol. 2013;27:1063–1070. doi:10.1111/jdv.12061

 PubMed Web of Science ®Google Scholar

Dreno B, Bagatin E, Blume-Peytavi U, Rocha M, Gollnick H. Female type of adult acne: physiological and psychological considerations and management. J Dtsch Dermatol Ges. 2018;16:1185–1194.

 Web of Science ®Google Scholar

Dreno B, Bordet C, Seite S, Taieb C. Acne relapses: impact on quality of life and productivity. J Eur Acad Dermatol Venereol. 2019;33:937–943. doi:10.1111/jdv.15419

 PubMed Web of Science ®Google Scholar

CCDS. Skinoren^® 20% Cream v1.0. LEO Pharma; 2022.

 Google Scholar